Introduction
Commercially available immunoassay kits are commonly used to screen for benzodiazepines in urine samples. The antibodies used in these kits are most often developed against one or several unconjugated benzodiazepines. Cross-reactivities toward the other benzodiazepines, which are similar in structure, facilitate their detection in the same screening assay.
Most benzodiazepines, however, are eliminated renally as their glucuronide conjugates rather than as free drugs. The low cross-reactivities of the immunoassay antibodies toward the benzodiazepine conjugates result in compromised detection limits. The importance of first hydrolyzing the benzodiazepine glucuronide with a [3-glucuronidase preparation before screening by immunoassay has been well documented (1) (2) (3) (4) (5) (6) .
Lorazepam has been one of the most difficult benzodiazepines to detect. Cross-reactivities of conjugated and free lorazepam are both low in most commercially available immunoassays. After a single dose, urinary lorazepam concentrations are usually less than 2000 ng/mL. When using EMIT It screening assay (Syva) with a 200-ng/mL cutoff, the drug was not detected in unhydrolyzed urine samples from subjects taking therapeutic doses of lorazepam, and it was detected in just 45% of the hydrolyzed urine samples from the same subjects (1).
The cloned enzyme donor immunoassay (CEDIA) technology is based on the assembly of an active [3-galactosidase (nitrazepam in the case of the benzodiazepine assay) enzyme from two inactive component parts. A hapten is attached to one of the enzyme parts in such a way as to not affect the enzymatic activity of the combined components. However, an antibody directed toward the hapten will prevent the joining of the enzyme components. When free hapten is added to the mixture via the serum sample, the antibody is consumed. Consequently, the enzyme activity is proportional to the amount of free hapten in the serum (7) .
Recently, the CEDIA dau Benzodiazepine assay kit was reformulated to include [3-glucuronidase in the reagent and an antibody with a higher cross-reactivity toward lorazepam. The kit performance was evaluated in four subjects by testing urine samples collected over a 48-h period following the ingestion of a single 1-mg lorazepam dose.
Methods

Subjects
Four healthy volunteers, two males and two females, each ingested a 1-mg tablet of lorazepam (Novolorazepam | Novopharm, Toronto, ON, Canada) at 8:00 a.m. A predose and 12 timed urine collections over the following intervals were procured: 0-2, 2-5, 5-8, 8--11, 11-14, 14-24, 24-26, 26--29, 29-32, 32-35, 35-38, and 38-48 h. There were no medication restrictions other than the consumption of a benzodiazepine. The absence of benzodiazepine metabolites was confirmed by analysis of the four predose urine samples by gas chromatography-mass spectrometry (8) . Aliquots of urine from each collection period were frozen at -70~ until analyzed.
Analysis
Urine samples were analyzed with the Microgenics CEDIA dau Benzodiazepines Assay according to the manufacturer's protocol on a Hitachi 717 analyzer (Boehringer Mannheim, Montreal, PQ, Canada). The assay was run in the semiquantitative mode. Supplied calibrators containing nitrazepam at 0, 200, 800, and 5000 ng/mL were used to prepare a log-logit calibration curve within the instrument. The E. coli [3-glucuronidase enzyme was added to the R1 reagent, which contained sheep polyclonal benzodiazepine antibody and half of a recombinant [3-galactosidase enzyme. When the urine sample was added to the R1 reagent, the lorazepam glucuronide was hydrolyzed. The free lorazepam then binds with the benzodiazepine antibody. After a 5-min incubation at 37~ the second reagent, R2, which contained the other half of the [3-galactosidase enzyme attached to a benzodiazepine (presumably nitrazepam), was added to the reaction well. The two [3-galactosidase enzyme halves can combine to form an active unit only when the benzodiazepine antibody is bound to the lorazepam in the sample. A second Hitachi channel was set up with the omission of the E. coli ~-glucuronidase from R1 reagent.
Each urine sample was assayed with and without E. coli hydrolysis. The E. coli enzyme activity in the sample plus R1 reagent mixture was calculated to be about 40,000 Fishmann units per milliliter. A second 1-mL urine aliquot was hydrolyzed with 5000 units of Helix pomatia ~-glucuronidase for 2 h at 56~ (1) and analyzed on the Hitachi channel without E. coli [3-glucuronidase.
Creatinine concentration was measured on all urine samples using the Jaffe method (9).
Results and Discussion
The response in the CEDIA dau Benzodiazepine assay as apparent nitrazepam equivalents (ng/mL) is displayed in Figure 1 for each of the four subjects. Without hydrolysis, all urine samples screened as negatives using 200 ng/mL as the cutoff concentration. With hydrolysis, the peak response mixture for 2 h at 56~ The hydrolysis conditions using Helix pornatia have been previously shown to be optimal for benzodiazepine conjugates (10) . In another study using urine spiked with lorazepam glucuronide, hydrolysis was shown to be nearly complete under these conditions (11, 12 obtained from Sigma Chemical (St. Louis, MO), which was used in the hydrolysis optimization studies (10) . The convenience of having the l~-glucuronidase incorporated into the reaction mixture outweighs the disadvantage of suboptimal hydrolysis yield. The time to the first negative result was consistently reduced by 3 h (e.g., 38 to 35 h) when E. coli was used in place of Helix pomatia. The E. Coli [3-glucuronidase was purchased separately from Boehringer Mannheim. A 5-mL bottle containing approximately 20 million Fishmann units costs $100 (U.S.). The shelf-life is approximately 1 year when stored at 4~ Each 110 test kit requires 90 pL of the enzyme added directly to the R1 reagent. The additional cost for the l~-glucuronidase is less than 2r per test.
In Figure 2 , the lorazepam response is corrected for urinary creatinine for the same four subjects. The response is expressed as apparent nitrazepam equivalents per milligram of creatinine (ng/mg). In each case, the curves are smoothed. If a 100-ng/mg creatinine cutoff is used, subjects 1 to 4 screened positive at 5-38, 5-35, 2-35, and 2-32 h, respectively. Creatinine correction extends the positive interval for subject I from 24 h out to 38 h. There is no difference in the positive time interval for the other three subjects. More trials are needed to assess possible the benefits of creatinine corrections.
The cross-reactivity of lorazepam in the CEDIA dau Benzodiazepine assay was determined by supplementing drug-free urine with lorazepam free base. The cross-reactivities ranged from 108 to 178% for lorazepam concentrations between 50 and 2500 ng/mL. At each lorazepam concentration there was little difference between the results from unhydrolyzed urine and urine which has been hydrolyzed with E. coli or Helix pomatia l~-glucuronidase. The findings are summarized in Figure 3 . Therefore, neither the hydrolysis procedure nor the [3-glucuronidase enzymes affected the CEDIA assay.
Lorazepam glucuronide was purchased from Alltech Applied Science (State College, PA) and used to supplement drug-free urine. The urine was spiked such that the lorazepam base concentrations were the same as those used in Figure 3 . These urine standards were subjected to the CEDIA Benzodiazepine assay without hydrolysis and with E. coli and Helixpomatia hydrolysis as described. The results are summarized in Figure  4 . The unhydrolyzed urines all gave cross-reactivities below 4%. The E. coli-treated urines gave cross-reactivities between 72 and 136%. The Helix pornatia-treated urines gave cross-reactivities between 84 and 134%. Most of the spiked urines gave a higher response using Helix pomatia than the corresponding urine treated with E. coil This reflects the slightly suboptimal Collectlon tlme (h) hydrolysis conditions also observed in the urine samples of subjects ingesting lorazepam.
